ClinicalTrials.gg
CompletedNCT04405076Updated Dec 30, 2022Results posted

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

A Phase 2 interventional study of Biological: mRNA-1273 and Placebo in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-30.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
15th of 36
660 · median 499
Started
2020
with 3 others
Phase 2
7 of 36
none open now
Registered
2nd of 36
by date
Lead sponsor
11 of 36
ModernaTX, Inc.

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 15th largest by enrollment, is one of 4 that started in 2020, is one of 7 in phase 2, and was the 2nd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.

Read the detailed description

This is a 3-part Phase 2a study, with Part A (Blinded Phase), Part B (Open-label Interventional Phase), and Part C (Rollover Proof of Concept).

Participants in Part A are blinded to their treatment assignment, with participants receiving either 2 active mRNA-1273 vaccine doses or placebo. Part B of the study is designed to offer participants to be unblinded so that participants who received placebo in Part A can request 2 doses of open-label mRNA-1273 vaccine. Additionally, participants who originally received 1 or 2 doses of mRNA-1273 (50 microgram [μg] or 100 μg vaccine) during Part A, will have the opportunity to request to receive a single booster dose of mRNA-1273.

Part C will be a proof-of-concept rollover study to evaluate a vaccine to treat mutations of SARS-CoV2, such as the S-protein of the B.1.351 variant. Part C will include approximately 60 participants, who are currently enrolled in Moderna's Phase 3 mRNA-1273-P301 study (NCT04470427), have already been unblinded, and have previously received 2 doses of mRNA-1273 at least 6 months earlier. At enrollment into Part C of this study, their participation in mRNA-1273-P301 study will be terminated. Part C will evaluate the safety and immunogenicity of 2 dose levels (20 µg and 50 µg) of mRNA-1273.351 and mRNA-1273/mRNA-1273.351 mixture (50 µg total), given as a single booster dose.

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273
  • mRNA-1273 vaccine
  • mRNA-1273.351
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID 19
  • COVID 19 Vaccine
  • Moderna
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 660 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Each participant must meet all of the following criteria during the screening period and at Day 1, unless noted otherwise, to be enrolled in this study:

  1. Male or female, 18 years of age or older at the time of consent (Screening Visit, Day 0). For Part B, participants must have been previously enrolled in the mRNA-1273 P201 study.
  2. Understands and agrees to comply with the study procedures and provides written .
  3. According to the assessment of the investigator, is in good general health and can comply with study procedures.
  4. Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or (defined as amenorrhea for ≥12 consecutive months prior to Screening (Day 0) without an alternative medical cause). A follicle-stimulating hormone (FSH) level may be measured at the discretion of the investigator to confirm postmenopausal status.
  5. Female participants of may be enrolled in the study if the participant fulfills all the following criteria:

    • Has a negative pregnancy test at Screening (Day 0) and on the day of the first injection (Day 1).
    • Has practiced adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1).
    • Has agreed to continue adequate contraception through 3 months following the second injection (Day 29).
    • Is not currently breastfeeding.

    Adequate female contraception is defined as consistent and correct use of a Food and Drug Administration (FDA) approved contraceptive method in accordance with the product label. For example:

    • Barrier method (such as condoms, diaphragm, or cervical cap) used in conjunction with spermicide
    • Intrauterine device
    • Prescription hormonal contraceptive taken or administered via oral (pill), transdermal (patch), subdermal, or IM route
    • Sterilization of a female participant's monogamous male partner prior to entry into the study Note: periodic abstinence (for example, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  6. Male participants engaging in activity that could result in pregnancy of sexual partners must agree to practice adequate contraception from the time of the first injection and through 3 months after the last injection.

Adequate contraception for male participants is defined as:

  • Monogamous relationship with a female partner using an intrauterine device or hormonal contraception (described above)
  • Use of barrier methods and spermicide
  • History of surgical sterilization
  • Male participants with partners who have become pregnant prior to Screening are eligible to participate in the study.

Additional Key Inclusion Criteria for Part C

  1. Participants must have been previously enrolled in the mRNA-1273-P301 study and must have received 2 doses of mRNA-1273 in Part A, has been unblinded and aware of their actual treatment in Study mRNA-1273-P301, must have been compliant in Study mRNA-1273-P301 (was not withdrawn or discontinued early), and has been at least 6 months since their second dose in Study mRNA-1273-P301 prior to enrollment in this part.

Key Exclusion Criteria:

Participants meeting any of the following criteria at the Screening Visit (Day 0) or at Day 1, unless noted otherwise, will be excluded from the study:

  1. Pregnant or breastfeeding.
  2. Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature ≥38.0°Celsius/100.4°Fahrenheit. Participants meeting this criterion may be rescheduled within the relevant window periods. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
  3. Current treatment with agents for prophylaxis against COVID-19.
  4. Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  5. Is a healthcare worker or a member of an emergency response team.
  6. Current use of any inhaled substance (for example, tobacco or cannabis smoke, nicotine vapors).
  7. History of chronic smoking (≥1 cigarette a day) within 1 year of the Screening Visit (Day 0).
  8. History of illegal substance use or alcohol abuse within the past 2 years. This exclusion does not apply to historical cannabis use that was formerly illegal in the participant's state but is legal at the time of Screening.
  9. Known history of hypertension, or systolic blood pressure >150 millimeter of mercury (mmHg) in participants in Cohort 1 (≥18 to \<55 years old) or systolic blood pressure >160 mmHg in participants in Cohort 2 (≥55 years old) at the Screening Visit (Day 0).
  10. Known history of hypotension or systolic blood pressure \<85 mmHg at the Screening Visit (Day 0).
  11. Diabetes mellitus
  12. Diagnosis of chronic pulmonary disease (for example, , asthma)
  13. Chronic cardiovascular disease
  14. Resides in a nursing home
  15. Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)
  16. Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other condition.
  17. Received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the Screening Visit (Day 0) (for ≥20 milligrams (mg)/day of prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to the Screening Visit (Day 0).
  18. Anticipating the need for immunosuppressive treatment at any time during participation in the study.
  19. Positive serology for virus surface antigen, virus antibody, or (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0).
  20. History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine.
  21. Bleeding disorder considered a to IM injection or phlebotomy.
  22. Diagnosis of within previous 10 years (excluding non-melanoma skin cancer).
  23. Has received or plans to receive a licensed vaccine ≤28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study injection. Licensed influenza vaccines may be received more than 14 days before or after any study injection.
  24. Receipt of systemic immunoglobulins or blood products within 3 months prior to the Screening Visit (Day 0) or plans for receipt during the study.
  25. Has donated ≥450 mL of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study.
  26. Participated in an interventional clinical study (other than mRNA-1273 P301) within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study.
  27. Is an immediate family member or household member of study personnel

Additional Key Exclusion Criteria for Part C

  1. Is SARS-CoV-2 positive by Reverse transcription polymerase chain reaction (RT-PCR) (central or local testing) at baseline or at any time during the mRNA-1273-P301 study regardless of the presence or absence of symptoms consistent with COVID-19.
  2. Had any SAE in the mRNA-1273-P301 study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
660 participants (actual)

Study arms

  • Experimental
    mRNA-1273: Dose 50 microgram (ug) - Participants Aged 18-54 years

    Part A: Participants aged 18-54 years will receive 1 intramuscular (IM) injection of 50 ug mRNA-1273 on Day 1 and on Day 29. Part B: Participants aged 18-54 years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.

    Biological: Biological: mRNA-1273

  • Experimental
    mRNA-1273: Dose 50 ug - Participants Aged 55+ years

    Part A: Participants aged 55+ years will receive 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29. Part B: Participants aged 55+ years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.

    Biological: Biological: mRNA-1273

  • Experimental
    mRNA-1273: Dose 100 ug - Participants Aged 18-54 years

    Part A: Participants aged 18-54 years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29. Part B: Participants aged 18-54 years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.

    Biological: Biological: mRNA-1273

  • Experimental
    mRNA-1273: Dose 100 ug - Participants Aged 55+ years

    Part A: Participants aged 55+ years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29. Part B: Participants aged 55+ years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.

    Biological: Biological: mRNA-1273

  • Placebo comparator
    Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 18-54 years

    Part A: Participants aged 18-54 years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29. Part B: Participants aged 18-54 who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29.

    Biological: Biological: mRNA-1273 · Biological: Placebo

  • Placebo comparator
    Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 55+ years

    Part A: Participants aged 55+ years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29. Part B: Participants aged 55+ years who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29.

    Biological: Biological: mRNA-1273 · Biological: Placebo

  • Experimental
    mRNA 1273.351 20 ug (Part C)

    Part C: Participants will receive 1 IM booster dose of 20 ug of mRNA 1273.351 on Day 1.

    Biological: mRNA-1273.351

  • Experimental
    mRNA 1273.351 50 ug (Part C)

    Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA 1273.351 on Day 1.

    Biological: mRNA-1273.351

  • Experimental
    mRNA-1273/mRNA-1273.351 mixture (Part C)

    Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA-1273/mRNA-1273.351 mixture on Day 1.

    Biological: Biological: mRNA-1273 · Biological: mRNA-1273.351

Interventions

  • Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

  • BiologicalmRNA-1273.351

    Sterile liquid for injection

07

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: 7 days post-vaccination

  2. Number of Participants With Unsolicited AEs

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Month 15), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Up to 28 days post-vaccination

  3. Number of Participants With Medically-Attended Adverse Events (MAAEs)

    An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Up to Month 15

  4. Number of Participants With SAEs

    An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

    Time frame: Up to Month 15

  5. Part A: Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-COV-2)-Specific Binding Antibody (bAb) as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)

    The geometric mean (GM) level of VAC58 spike immunoglobulin G (IgG) antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 1 and ULOQ was 2052. The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.

    Time frame: Days 1 (Baseline), 29, 43, 57, and 209

  6. Part B: Level of SARS-CoV-2-Specific bAb as Measured by ELISA

    The GM level of VAC65 spike IgG antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 1 and ULOQ was 2052. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.

    Time frame: Days 1 (Baseline) and 29

  7. Part C: Level of SARS-CoV-2-Specific bAb as Measured by MSD

    The GM level of SARS-CoV-2 protein antibody against B.1.351, as measured by MSD MULTIPLEX is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 18 and ULOQ was 4200000. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.

    Time frame: Days 1 (Baseline), 8, 15, and 29

Secondary outcomes

  1. Part A: Titer of SARS-CoV-2-Specific Neutralizing Antibody (nAb)

    The GM titer (microneutralization \[MN\] and MN50) of serum nAb against SARS-CoV-2 as measured by live virus MN assays is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280 at Days 1 (Baseline), 29, 43, and 57. For MN50, LLOQ was 91.10 and ULOQ was 2031.87 at Days 1 (Baseline), 29, 43, and 57. For MN, LLOQ was 160 and ULOQ was 1280 at Day 209. For MN50, LLOQ was 318.46 and ULOQ was 1917.83 at Day 209. The 95% CI was calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM titer, then back transformed to the original scale for presentation.

    Time frame: Days 1 (Baseline), 29, 43, 57, and 209

  2. Part B: Titer of SARS-CoV-2-Specific nAb

    The GM titer (50% inhibitory dose \[ID50\], 80% inhibitory dose \[ID80\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 18.5 and ULOQ was 45118 for IC50. LLOQ was 14.3 and ULOQ was 10232 for ID80. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.

    Time frame: Days 1 (Baseline), 29, and 181

  3. Part C: Titer of SARS-CoV-2-Specific nAb

    The GM titer (ID50, ID80) of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \[B.1.351\]) as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. For NAb ID50 Titers, LLOQ was 18.5 and ULOQ was 45118. For NAb ID80 Titers, LLOQ was 14.3 and ULOQ was 10232. For NAb ID50 Titers against B.1.351, LLOQ was 19.5 and ULOQ was 385.7. For NAb ID80 Titers against B.1.351, LLOQ was 12.5 and ULOQ was 102.2. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation.

    Time frame: Days 1 (Baseline), 8, 15, 29, and 181

  4. Part A: Percentage of Participants With Seroconversion From Baseline

    Based on MN titers and MN50 titers of serum nAb against SARS-CoV-2 as measured by live virus MN assays, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using the Clopper-Pearson method at each post-baseline timepoint. Seroconversion at a participant level was defined as a change of nAb titer from below the limit of detection (LOD) or LLOQ to equal to or above LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280. For MN50, LLOQ was 91.10 and ULOQ was 2031.87.

    Time frame: Days 29, 43, and 57

  5. Part B: Percentage of Participants With Seroconversion From Baseline

    Based on ID50 and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay, % of participants with seroconversion from baseline reported with 2-sided 95% CI using Clopper-Pearson method at each postbaseline timepoint. Seroconversion at participant level defined as change of nAb titer from below LOD or LLOQ to equal to or above LOD or LLOQ (respectively) or 4-times or higher titer ratio in participants with preexisting nAb titers. Antibody values \<LLOQ replaced by 0.5\*LLOQ. Values \>ULOQ converted to ULOQ. LLOQ: 18.5 and ULOQ: 45118 for IC50. LLOQ: 14.3 and ULOQ: 10232 for ID80. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation. PP Set: participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.

    Time frame: Days 29 and 181

  6. Part C: Percentage of Participants With Seroconversion From Baseline

    Based on ID50 titers and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \[B.1.351\]) as measured by pseudovirus nAb assay, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using Clopper-Pearson method at each post-baseline timepoint. Seroconversion at participant level defined as a change of nAb titer from below LOD or LLOQ ≥LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values \>ULOQ were converted to ULOQ. NAb ID50 Titers: LLOQ was 18.5 and ULOQ was 45118. NAb ID80 Titers: LLOQ was 14.3 and ULOQ was 10232. NAb ID50 Titers against B.1.351: LLOQ was 19.5 and ULOQ was 385.7. NAb ID80 Titers against B.1.351: LLOQ was 12.5 and ULOQ was 102.2. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation.

    Time frame: Days 8, 15, 29, and 181

08

Results

Posted Dec 30, 2022

Participant flow

Participants in Part A were blinded to study treatment. After completion of Part A, participants could have chosen to be unblinded and to participate in Part B (open-label). Participants in Part C (proof-of-concept rollover) were unblinded and had received 2 doses of mRNA-1273 in Study mRNA-1273-P301 (Study P301; NCT04470427).

Part A (Blinded Phase)
Participant flow — Part A (Blinded Phase)
MilestonePart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273Part B: Placebo Then 100 ug mRNA-1273Part C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
Started200200200000000
Received at least 1 dose of study drug during part a200200200000000
Completed188185182000000
Not completed121518000000
Withdrew: Lost to follow-up667000000
Withdrew: Physician decision120000000
Withdrew: Protocol violation338000000
Withdrew: Withdrawal of consent (covid-19 non-infection related)100000000
Withdrew: Withdrawal of consent (other)140000000
Withdrew: Other than specified003000000
Part B (Open-Label Interventional Phase)
Participant flow — Part B (Open-Label Interventional Phase)
MilestonePart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273Part B: Placebo Then 100 ug mRNA-1273Part C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
Started000173171158000
Received at least 1 dose of study drug during part b000173171158000
Completed000161166152000
Not completed0001256000
Withdrew: Withdrawal by subject000614000
Withdrew: Physician decision000010000
Withdrew: Lost to follow-up000632000
Part C (Rollover Proof of Concept)
Participant flow — Part C (Rollover Proof of Concept)
MilestonePart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273Part B: Placebo Then 100 ug mRNA-1273Part C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
Started000000202020
Completed000000181819
Not completed000000221
Withdrew: Withdrawal of consent (other)000000021
Withdrew: Lost to follow-up000000200

Outcome measures

PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
7 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsPart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273Part B: Placebo Then 100 ug mRNA-1273Part C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
Grade 1956972657350131012
Grade 2619021595971623
Grade 325326291828022
Grade 4000000000
PrimaryNumber of Participants With Unsolicited AEs

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Month 15), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Up to 28 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited AEs
ParticipantsPart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273Part B: Placebo Then 100 ug mRNA-1273Part C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
Number of Participants With Unsolicited AEs575651172542334
PrimaryNumber of Participants With Medically-Attended Adverse Events (MAAEs)

An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Up to Month 15
Reported as:
Count of participants · Participants
Number of Participants With Medically-Attended Adverse Events (MAAEs)
ParticipantsPart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273Part B: Placebo Then 100 ug mRNA-1273Part C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
Number of Participants With Medically-Attended Adverse Events (MAAEs)743864424759737
PrimaryNumber of Participants With SAEs

An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.

Time frame:
Up to Month 15
Reported as:
Count of participants · Participants
Number of Participants With SAEs
ParticipantsPart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273Part B: Placebo Then 100 ug mRNA-1273Part C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
Number of Participants With SAEs520222010
PrimaryPart A: Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-COV-2)-Specific Binding Antibody (bAb) as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)

The geometric mean (GM) level of VAC58 spike immunoglobulin G (IgG) antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 1 and ULOQ was 2052. The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.

Time frame:
Days 1 (Baseline), 29, 43, 57, and 209
Reported as:
Geometric mean · arbitrary units per mL (AU/mL)
Part A: Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-COV-2)-Specific Binding Antibody (bAb) as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)
arbitrary units per mL (AU/mL)Part A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: Placebo
Day 1 (Baseline)0.70 (0.63 to 0.78)0.67 (0.60 to 0.73)0.67 (0.61 to 0.73)
Day 2959.42 (52.05 to 67.82)81.51 (70.19 to 94.67)0.68 (0.61 to 0.76)
Day 43720.85 (660.30 to 786.96)834.66 (765.28 to 910.33)0.65 (0.59 to 0.71)
Day 57519.48 (474.00 to 569.33)647.22 (588.98 to 711.21)0.67 (0.60 to 0.75)
Day 20997.02 (87.58 to 107.47)128.00 (114.44 to 143.18)0.91 (0.73 to 1.14)
PrimaryPart B: Level of SARS-CoV-2-Specific bAb as Measured by ELISA

The GM level of VAC65 spike IgG antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 1 and ULOQ was 2052. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.

Time frame:
Days 1 (Baseline) and 29
Reported as:
Geometric mean · AU/mL
Part B: Level of SARS-CoV-2-Specific bAb as Measured by ELISA
AU/mLPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273
Day 1 (Baseline)86.29 (76.89 to 96.83)109.56 (96.79 to 124.02)
Day 291069.73 (992.92 to 1152.49)1083.21 (1018.75 to 1151.75)
SecondaryPart A: Titer of SARS-CoV-2-Specific Neutralizing Antibody (nAb)

The GM titer (microneutralization \[MN\] and MN50) of serum nAb against SARS-CoV-2 as measured by live virus MN assays is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280 at Days 1 (Baseline), 29, 43, and 57. For MN50, LLOQ was 91.10 and ULOQ was 2031.87 at Days 1 (Baseline), 29, 43, and 57. For MN, LLOQ was 160 and ULOQ was 1280 at Day 209. For MN50, LLOQ was 318.46 and ULOQ was 1917.83 at Day 209. The 95% CI was calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM titer, then back transformed to the original scale for presentation.

Time frame:
Days 1 (Baseline), 29, 43, 57, and 209
Reported as:
Geometric mean · titers
Part A: Titer of SARS-CoV-2-Specific Neutralizing Antibody (nAb)
titersPart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: Placebo
MN, Day 1 (Baseline)20.6 (20.0 to 21.2)20.6 (19.7 to 21.5)20.8 (20.1 to 21.4)
MN, Day 29112.2 (94.9 to 132.7)149.6 (127.3 to 175.9)21.9 (20.5 to 23.5)
MN, Day 431145.4 (1101.3 to 1191.1)1185.8 (1142.9 to 1230.3)21.2 (20.1 to 22.4)
MN, Day 571090.6 (1038.9 to 1144.9)1095.5 (1041.5 to 1152.2)21.8 (20.4 to 23.4)
MN, Day 209254.4 (219.4 to 294.9)354.8 (309.2 to 407.2)85.3 (80.6 to 90.2)
MN50, Day 1 (Baseline)46.500 (45.425 to 47.600)46.684 (44.957 to 48.477)47.109 (45.745 to 48.512)
MN50, Day 29173.750 (148.550 to 203.225)227.433 (194.207 to 266.343)49.231 (46.355 to 52.285)
MN50, Day 431761.660 (1690.216 to 1836.124)1813.480 (1741.280 to 1888.673)48.059 (45.820 to 50.408)
MN50, Day 571632.442 (1550.245 to 1718.998)1656.064 (1570.464 to 1746.330)49.141 (46.267 to 52.194)
MN50, Day 209401.508 (350.667 to 459.720)538.798 (472.772 to 614.045)167.002 (159.249 to 175.133)
SecondaryPart B: Titer of SARS-CoV-2-Specific nAb

The GM titer (50% inhibitory dose \[ID50\], 80% inhibitory dose \[ID80\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 18.5 and ULOQ was 45118 for IC50. LLOQ was 14.3 and ULOQ was 10232 for ID80. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.

Time frame:
Days 1 (Baseline), 29, and 181
Reported as:
Geometric mean · titers
Part B: Titer of SARS-CoV-2-Specific nAb
titersPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273
ID50, Day 1 (Baseline)104.658 (88.282 to 124.070)150.224 (125.726 to 179.495)
ID50, Day 291834.309 (1600.233 to 2102.623)1951.735 (1729.606 to 2202.392)
ID50, Day 181915.331 (622.504 to 1345.904)673.273 (578.167 to 784.025)
ID80, Day 1 (Baseline)39.646 (33.789 to 46.518)55.686 (47.459 to 65.341)
ID80, Day 29696.085 (609.203 to 795.358)736.617 (661.040 to 820.835)
ID80, Day 181291.791 (203.597 to 418.189)228.635 (197.044 to 265.291)
SecondaryPart C: Titer of SARS-CoV-2-Specific nAb

The GM titer (ID50, ID80) of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \[B.1.351\]) as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. For NAb ID50 Titers, LLOQ was 18.5 and ULOQ was 45118. For NAb ID80 Titers, LLOQ was 14.3 and ULOQ was 10232. For NAb ID50 Titers against B.1.351, LLOQ was 19.5 and ULOQ was 385.7. For NAb ID80 Titers against B.1.351, LLOQ was 12.5 and ULOQ was 102.2. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation.

Time frame:
Days 1 (Baseline), 8, 15, 29, and 181
Reported as:
Geometric mean · titers
Part C: Titer of SARS-CoV-2-Specific nAb
titersPart C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
ID50 Against Original Strain, Day 1 (Baseline)196.107 (133.338 to 288.424)156.011 (80.546 to 302.180)79.572 (53.625 to 118.074)
ID50 Against Original Strain, Day 81089.901 (748.146 to 1587.770)1568.894 (1030.722 to 2388.062)1183.096 (900.313 to 1554.700)
ID50 Against Original Strain, Day 152221.382 (1434.353 to 3440.255)1725.415 (1212.131 to 2456.053)3082.946 (1891.502 to 5024.874)
ID50 Against Original Strain, Day 291808.133 (1323.211 to 2470.767)1757.179 (1117.782 to 2762.324)3691.896 (2330.908 to 5847.548)
ID50 Against Original Strain, Day 181—512.129 (303.261 to 864.853)—
ID80 Against Original Strain, Day 1 (Baseline)76.279 (53.035 to 109.712)56.344 (33.804 to 93.911)30.774 (21.565 to 43.915)
ID80 Against Original Strain, Day 8448.109 (300.430 to 668.381)500.158 (341.180 to 733.214)458.435 (351.348 to 598.161)
ID80 Against Original Strain, Day 15730.018 (509.454 to 1046.073)678.926 (462.561 to 996.498)947.774 (647.781 to 1386.696)
ID80 Against Original Strain, Day 29632.263 (460.549 to 868.001)615.967 (397.103 to 955.460)1156.267 (743.617 to 1797.907)
ID80 Against Original Strain, Day 181—182.837 (108.300 to 308.673)—
ID50 Against B.1.351, Day 1 (Baseline)45.574 (28.832 to 72.036)32.026 (19.758 to 51.911)18.338 (13.572 to 24.776)
ID50 Against B.1.351, Day 8919.281 (592.738 to 1425.720)1088.511 (670.315 to 1767.610)706.141 (456.010 to 1093.475)
ID50 Against B.1.351, Day 151088.432 (736.353 to 1608.854)1113.392 (652.885 to 1898.716)1166.830 (760.230 to 1790.895)
ID50 Against B.1.351, Day 291537.029 (1066.352 to 2215.458)1116.885 (714.119 to 1746.813)1129.955 (742.454 to 1719.699)
ID50 Against B.1.351, Day 181—141.773 (76.471 to 262.839)—
ID80 Against B.1.351, Day 1 (Baseline)17.403 (10.870 to 27.863)15.046 (10.088 to 22.442)8.326 (6.727 to 10.306)
ID80 Against B.1.351, Day 8289.360 (196.260 to 426.626)313.644 (203.582 to 483.210)225.475 (160.419 to 316.915)
ID80 Against B.1.351, Day 15435.078 (300.742 to 629.418)371.579 (228.889 to 603.223)413.424 (284.856 to 600.020)
ID80 Against B.1.351, Day 29486.398 (341.630 to 692.511)345.827 (214.472 to 557.633)362.540 (249.138 to 527.560)
ID80 Against B.1.351, Day 181—55.887 (29.969 to 104.220)—
SecondaryPart A: Percentage of Participants With Seroconversion From Baseline

Based on MN titers and MN50 titers of serum nAb against SARS-CoV-2 as measured by live virus MN assays, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using the Clopper-Pearson method at each post-baseline timepoint. Seroconversion at a participant level was defined as a change of nAb titer from below the limit of detection (LOD) or LLOQ to equal to or above LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280. For MN50, LLOQ was 91.10 and ULOQ was 2031.87.

Time frame:
Days 29, 43, and 57
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Seroconversion From Baseline
percentage of participantsPart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: Placebo
MN Titer, Day 2978.0 (70.9 to 84.0)88.9 (83.4 to 93.1)1.7 (0.3 to 4.8)
MN Titer, Day 43100 (97.4 to 100.0)100 (97.6 to 100.0)0.6 (0.0 to 3.1)
MN Titer, Day 57100 (97.6 to 100.0)100 (97.6 to 100.0)1.8 (0.4 to 5.0)
MN50 Titer, Day 2965.5 (57.8 to 72.6)76.7 (69.8 to 82.6)1.1 (0.1 to 4.0)
MN50 Titer, Day 43100 (97.4 to 100.0)100 (97.6 to 100.0)0.6 (0.0 to 3.1)
MN50 Titer, Day 57100 (97.6 to 100.0)100 (97.6 to 100.0)1.8 (0.4 to 5.0)
SecondaryPart B: Percentage of Participants With Seroconversion From Baseline

Based on ID50 and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay, % of participants with seroconversion from baseline reported with 2-sided 95% CI using Clopper-Pearson method at each postbaseline timepoint. Seroconversion at participant level defined as change of nAb titer from below LOD or LLOQ to equal to or above LOD or LLOQ (respectively) or 4-times or higher titer ratio in participants with preexisting nAb titers. Antibody values \<LLOQ replaced by 0.5\*LLOQ. Values \>ULOQ converted to ULOQ. LLOQ: 18.5 and ULOQ: 45118 for IC50. LLOQ: 14.3 and ULOQ: 10232 for ID80. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation. PP Set: participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.

Time frame:
Days 29 and 181
Reported as:
Geometric mean · percentage of participants
Part B: Percentage of Participants With Seroconversion From Baseline
percentage of participantsPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273
ID50, Day 2992.4 (86.8 to 96.2)87.9 (81.6 to 92.7)
ID50, Day 18181.6 (65.7 to 92.3)54.4 (46.0 to 62.6)
ID80, Day 2995.2 (90.3 to 98.0)93.3 (88.0 to 96.7)
ID80, Day 18178.9 (62.7 to 90.4)53.7 (45.3 to 62.0)
SecondaryPart C: Percentage of Participants With Seroconversion From Baseline

Based on ID50 titers and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \[B.1.351\]) as measured by pseudovirus nAb assay, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using Clopper-Pearson method at each post-baseline timepoint. Seroconversion at participant level defined as a change of nAb titer from below LOD or LLOQ ≥LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values \>ULOQ were converted to ULOQ. NAb ID50 Titers: LLOQ was 18.5 and ULOQ was 45118. NAb ID80 Titers: LLOQ was 14.3 and ULOQ was 10232. NAb ID50 Titers against B.1.351: LLOQ was 19.5 and ULOQ was 385.7. NAb ID80 Titers against B.1.351: LLOQ was 12.5 and ULOQ was 102.2. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation.

Time frame:
Days 8, 15, 29, and 181
Reported as:
Geometric mean · percentage of participants
Part C: Percentage of Participants With Seroconversion From Baseline
percentage of participantsPart C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
ID50 Against Original Strain, Day 847.4 (24.4 to 71.1)78.9 (54.4 to 93.9)100 (83.2 to 100.0)
ID50 Against Original Strain, Day 1578.9 (54.4 to 93.9)90.0 (68.3 to 98.8)95.0 (75.1 to 99.9)
ID50 Against Original Strain, Day 2984.2 (60.4 to 96.6)95.0 (75.1 to 99.9)100 (83.2 to 100.0)
ID50 Against Original Strain, Day 181—38.9 (17.3 to 64.3)—
ID80 Against Original Strain, Day 868.4 (43.4 to 87.4)84.2 (60.4 to 96.6)95.0 (75.1 to 99.9)
ID80 Against Original Strain, Day 1584.2 (60.4 to 96.6)95.0 (75.1 to 99.9)100 (83.2 to 100.0)
ID80 Against Original Strain, Day 2984.2 (60.4 to 96.6)95.0 (75.1 to 99.9)95.0 (75.1 to 99.9)
ID80 Against Original Strain, Day 181—38.9 (17.3 to 64.3)—
ID50 Against B.1.351, Day 8100 (82.4 to 100.0)100 (82.4 to 100.0)100 (83.2 to 100.0)
ID50 Against B.1.351, Day 1594.7 (74.0 to 99.9)100 (83.2 to 100.0)100 (83.2 to 100.0)
ID50 Against B.1.351, Day 29100 (82.4 to 100.0)100 (83.2 to 100.0)100 (83.2 to 100.0)
ID50 Against B.1.351, Day 181—61.1 (35.7 to 82.7)—
ID80 Against B.1.351, Day 894.7 (74.0 to 99.9)94.7 (74.0 to 99.9)100 (83.2 to 100.0)
ID80 Against B.1.351, Day 1594.7 (74.0 to 99.9)100 (83.2 to 100.0)100 (83.2 to 100.0)
ID80 Against B.1.351, Day 29100 (82.4 to 100.0)100 (83.2 to 100.0)100 (83.2 to 100.0)
ID80 Against B.1.351, Day 181—55.6 (30.8 to 78.5)—
PrimaryPart C: Level of SARS-CoV-2-Specific bAb as Measured by MSD

The GM level of SARS-CoV-2 protein antibody against B.1.351, as measured by MSD MULTIPLEX is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 18 and ULOQ was 4200000. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.

Time frame:
Days 1 (Baseline), 8, 15, and 29
Reported as:
Geometric mean · AU/mL
Part C: Level of SARS-CoV-2-Specific bAb as Measured by MSD
AU/mLPart C: 20 ug mRNA-1273.35150 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
Day 1 (Baseline)59742.3 (43057.8 to 82891.8)44921.5 (28539.6 to 70706.5)33409.8 (25264.8 to 44180.6)
Day 8240180.0 (166361.1 to 346754.3)267002.2 (199939.9 to 356558.2)228572.0 (178986.7 to 291894.2)
Day 15297880.2 (224089.6 to 395969.4)418215.3 (311988.7 to 560610.2)384521.1 (282461.4 to 523457.3)
Day 29297962.7 (227337.5 to 390528.5)345765.9 (251640.5 to 475098.5)367714.1 (268913.2 to 502815.1)

Adverse events

Collected over Up to Month 15. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: 50 ug mRNA-12730/200 (0%)5/200 (2.5%)105/200 (52.5%)
Part A: 100 ug mRNA-12730/200 (0%)2/200 (1%)76/200 (38%)
Part A: Placebo0/200 (0%)0/200 (0%)94/200 (47%)
Part B: 50 ug mRNA-1273 Then 50 ug mRNA-12730/173 (0%)2/173 (1.2%)51/173 (29.5%)
Part B: 100 ug mRNA-1273 Then 50 ug mRNA-12730/171 (0%)2/171 (1.2%)62/171 (36.3%)
Part B: Placebo Then 100 ug mRNA-12730/158 (0%)2/158 (1.3%)70/158 (44.3%)
Part C: 20 ug mRNA-1273.3510/20 (0%)0/20 (0%)8/20 (40%)
Part C: 50 ug mRNA-1273.3510/20 (0%)1/20 (5%)4/20 (20%)
Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture0/20 (0%)0/20 (0%)9/20 (45%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273Part B: Placebo Then 100 ug mRNA-1273Part C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
Pancreatic carcinoma stage IVInfections and infestations0/2000/2000/2000/1730/1710/1580/201/200/20
BradycardiaCardiac disorders1/2000/2000/2000/1730/1711/1580/200/200/20
SepsisInfections and infestations0/2000/2000/2000/1730/1711/1580/200/200/20
Atrioventricular block completeCardiac disorders0/2000/2000/2000/1730/1711/1580/200/200/20
Peptic ulcer perforationGastrointestinal disorders0/2000/2000/2000/1730/1711/1580/200/200/20
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2000/2000/2000/1731/1710/1580/200/200/20
Tendon ruptureInjury, poisoning and procedural complications0/2000/2000/2000/1731/1710/1580/200/200/20
PericarditisCardiac disorders0/2000/2000/2001/1730/1710/1580/200/200/20
Deep vein thrombosisVascular disorders0/2000/2000/2001/1730/1710/1580/200/200/20
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2000/2000/2001/1730/1710/1580/200/200/20
Most frequent other events
Showing 10 of 270
Most frequent other events
EventPart A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart B: 50 ug mRNA-1273 Then 50 ug mRNA-1273Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273Part B: Placebo Then 100 ug mRNA-1273Part C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture
MyalgiaMusculoskeletal and connective tissue disorders6/2002/2003/2000/1734/1712/1580/201/203/20
COVID-19Infections and infestations3/2002/20026/2009/1738/17116/1580/200/200/20
DepressionPsychiatric disorders3/2004/2002/2000/1730/1710/1582/200/201/20
HypertensionVascular disorders5/2001/2000/2002/1730/1712/1580/202/202/20
ArthralgiaMusculoskeletal and connective tissue disorders7/2004/2004/2001/1732/1712/1580/201/202/20
Pharyngitis streptococcalInfections and infestations0/2000/2000/2000/1730/1710/1582/200/200/20
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2000/2000/2000/1730/1710/1580/200/202/20
HeadacheNervous system disorders16/2009/2008/2003/1738/1711/1580/200/201/20
FatigueGeneral disorders16/2005/2007/2001/1737/1715/1580/201/201/20
Urinary tract infectionInfections and infestations3/2002/2003/2000/1732/1712/1581/200/200/20

Baseline characteristics

Safety Set: All participants who received any study injection in their respective part of the study. Note, participants who received placebo in Part A, received 100 ug mRNA-1273 in Part B (N=158). Participants who received 50 or 100 ug mRNA-1273 in Part A, received 50 ug mRNA-1273 in Part B (N=344). Since Baseline Characteristics data for participants in Part B are included in Part A, separate columns are not reported here for Part B.

Age, Customized
Age, Customized(Participants)Part A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 MixtureTotal
Between 18 and 55 years1001001001399331
>=55 years10010010071111329
Sex: Female, Male
Sex: Female, Male(Participants)Part A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 MixtureTotal
Female1371241291598422
Male63767151112238
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 MixtureTotal
Hispanic or Latino15161610149
Not Hispanic or Latino184184184192019610
Unknown or Not Reported1000001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Part A: 50 ug mRNA-1273Part A: 100 ug mRNA-1273Part A: PlaceboPart C: 20 ug mRNA-1273.351Part C: 50 ug mRNA-1273.351Part C: 50 ug mRNA-1273/mRNA-1273.351 MixtureTotal
White188188193201919627
Black or African American58300016
Asian2230108
American Indian or Alaska Native2100014
Native Hawaiian or Other Pacific Islander1000001
Multiracial1010002
Other1100002
09

Study locations

8 sites
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Alliance for Multispecialty Research
    Newton, Kansas 67114, United States
  • Alliance for Multispecialty Research
    Kansas City, Missouri 64114, United States
  • Meridian Clinical Research
    Norfolk, Nebraska 68701, United States
  • Trial Management Associates
    Wilmington, North Carolina 28403, United States
  • Meridian Clinical Research
    Dakota Dunes, South Dakota 57049, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Benchmark Research
    San Angelo, Texas 76904, United States
10

References and documents

Publications

  • Kirste I, Hortsch S, Grunert VP, Legault H, Maglinao M, Eichenlaub U, Kashlan B, Pajon R, Jochum S. Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19. Infect Dis Ther. 2023 Jan;12(1):177-191. doi: 10.1007/s40121-022-00711-y. Epub 2022 Nov 15. PubMed 36376733 ↗
  • Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, Carfi A, Edwards DK, Oestreicher J, Legault H, Dutko FJ, Girard B, Pajon R, Miller JM, Das R, Leav B, McPhee R. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med. 2022 May;28(5):1042-1049. doi: 10.1038/s41591-022-01739-w. Epub 2022 Mar 3. PubMed 35241844 ↗
  • Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, Nunna N, Huang W, Oestreicher J, Colpitts T, Bennett H, Legault H, Paila Y, Nestorova B, Ding B, Montefiori D, Pajon R, Miller JM, Leav B, Carfi A, McPhee R, Edwards DK. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021 Nov;27(11):2025-2031. doi: 10.1038/s41591-021-01527-y. Epub 2021 Sep 15. PubMed 34526698 ↗
  • Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, Leav B; mRNA-1273 Study Group. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021 May 12;39(20):2791-2799. doi: 10.1016/j.vaccine.2021.02.007. Epub 2021 Feb 9. PubMed 33707061 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Oct 2021, 16 months.

Results were first posted in Dec 2022, 1 year 2 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 16 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2020
First posted
May 28, 2020
StartActual
May 29, 2020
Primary completionActual
Oct 28, 2021
CompletionActual
Oct 28, 2021
Results first posted
Dec 30, 2022
Last update
Dec 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04405076
Lead sponsor
ModernaTX, Inc.
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
May 28, 2020
Start date
May 29, 2020
Primary completion
Oct 28, 2021
Completion
Oct 28, 2021
Results posted
Dec 30, 2022
Last update
Dec 30, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273

Start the discussion